Our lead is a small molecule called amitifadine (formerly DOV 21,947, EB-1010). This molecule is known as a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) or triple uptake inhibitor because amitifadine modulates the amounts of these three neurotransmitters in the brain. These three neurotransmitters are important in many conditions and disorders including: pain, mood, cognition, sexual function, and appetite.

Amitifadine is well known and has been studied for appetite, pain, and especially, depression. The Ethismos team has accumulated over a decade of research and development on amitifadine and has conducted 10 human trials and amassed corresponding safety and efficacy data. A comprehensive preclinical testing program necessary for registration is advanced, and the Ethismos team and collaborating partners conducting Phase 2 clinical trials for several indications of high unmet medical need: treatment of chronic musculoskeletal low back pain, and chronic pain prevention with ongoing research in several other indications.

The Ethismos team and our collaborating partners are among the best and brightest scientist, researchers and clinicians in the world. We are driven by a common passion to discover, develop and advance therapies to prevent chronic pain that affects up to half those undergoing major surgery.

Ethismos is also focused on treating chronic pain with an emphasis on the emotional symptoms of pain that are currently untreated by standard medications today.